Abnormal Bleeding Deserves an Answer: When an Endometrial Biopsy Is Needed

So the rule is worth stating plainly. Postmenopausal bleeding is endometrial cancer until proven otherwise. That does not mean it usually is cancer, most of the time it is not. It means the bleeding earns an evaluation every single time, and there is a clear, well-defined path for doing that.

Why bleeding after menopause is a red flag, not a nuisance

Postmenopausal bleeding means any bleeding from the uterus 12 or more months after your final period. There is no small amount that gets a pass. Spotting counts.

The reason clinicians take it so seriously is a single number. About 90 percent of endometrial cancers announce themselves through abnormal bleeding, per the National Cancer Institute. That makes bleeding the early-warning signal for the most common gynecologic cancer in high-income countries, and endometrial cancer has been rising in the United States for decades, per ACOG.

Here is the reassuring half. Only about 10 to 15 percent of women with postmenopausal bleeding turn out to have cancer, per the National Cancer Institute. Most causes are benign: a thinned, fragile lining (atrophy), a polyp, or hormone therapy. But the split between the benign majority and the dangerous minority cannot be made by feel, and the stakes reward speed. Endometrial cancer found early is roughly 95 percent survivable at five years, against under 20 percent once it has spread to distant sites, per SEER data. That gap is the whole argument for evaluating every episode.

The risk factors that decide when premenopausal bleeding gets a biopsy

Before menopause the picture is noisier, because irregular bleeding is common and usually benign. Risk factors are what move a case from watch to biopsy.

ACOG sets a clean line on age. For abnormal uterine bleeding, endometrial sampling is first-line in anyone older than 45. Under 45, sampling is warranted when there is a history of unopposed estrogen exposure, when medical management has failed, or when bleeding persists.

Unopposed estrogen is the thread running through most of the risk. Estrogen tells the endometrium to grow, and progesterone keeps that growth in check. When estrogen acts without enough progesterone to balance it, the lining proliferates, and sustained proliferation is the soil endometrial cancer and its precursor, endometrial hyperplasia, grow in. The common drivers all trace back to this:

• Obesity. Fat tissue converts other hormones into estrogen, raising estrogen exposure, and it is a well-established risk factor per the American Cancer Society.
• PCOS and chronic anovulation. Cycles without ovulation leave the lining under estrogen without the progesterone a normal cycle supplies. PCOS carries roughly a 2.7-fold increased risk of endometrial cancer in the published cohort data.
• Estrogen-only hormone therapy taken without progesterone, per the American Cancer Society.
• Lynch syndrome. This inherited mismatch-repair condition raises the lifetime endometrial cancer risk sharply, up to roughly 40 to 60 percent depending on the specific gene. A personal or family history that suggests it changes the threshold to act.

If you have abnormal bleeding and one of these applies, that is the case where the biopsy is not optional.

The two tools: an ultrasound measurement and a tissue sample

Two tests carry the workup, and it helps to know what each one actually does.

A transvaginal ultrasound measures the thickness of the endometrium. The classic postmenopausal threshold is about 4 mm: a thin, fully seen lining points away from cancer. Reading the number in context matters, which is what a good how to read an ultrasound report walk-through is for. But the threshold has a real limit. Studies found that ultrasound alone missed 5 to 12 percent of cancers at first presentation, which is why ACOG updated its guidance in 2026: for most patients with postmenopausal bleeding, the recommendation is now both a transvaginal ultrasound and an endometrial tissue sample at the initial visit, not ultrasound first. Ultrasound alone stays acceptable only for a select patient, one episode of bleeding, an endometrium fully visualized at 4 mm or less, no strong risk factors, and counseling that any recurrence needs immediate re-evaluation.

The endometrial biopsy is the tissue answer. It is an office procedure that samples the lining, and the sample goes to pathology. The result comes back as a pathology report that sorts the tissue into benign, hyperplasia (with or without atypia, the atypical form now called endometrial intraepithelial neoplasia), or carcinoma.

What the biopsy result means, and when a negative is not the end

A benign biopsy is common and usually the end of the story. But there is one trap worth naming. An office biopsy samples the lining blindly, so it can miss a focal lesion like a polyp tucked in one spot. If the biopsy is benign and the bleeding continues, the workup is not finished. The next step is usually a look inside with hysteroscopy, or a dilation and curettage, to sample directly.

Reading the report itself takes some fluency. Terms like proliferative, atrophic, hyperplasia, and atypia each carry a different next step, and a plain-language how to read a biopsy result guide keeps you from reading more or less into the words than they say. The single most useful instinct is the same one that started this: match the result against the bleeding. A tidy report that leaves your symptom unexplained is a reason to keep asking, not to stop.

How Healz turns a scattered bleeding workup into one clear answer

An abnormal-bleeding workup produces disconnected pieces: an ultrasound report with a thickness measurement, a biopsy read out as a pathology report, and a list of risk factors sitting quietly in your history. Healz puts all of it in one chat, not ten apps.

Healz is equipped with root-cause technology. That is why it does not settle for "probably hormonal." It reads your bleeding pattern, your ultrasound measurement, and your risk profile together, cross-checks the whole picture against 1M+ rare cases, and drills toward the actual driver, so a benign biopsy that still leaves the bleeding unexplained is flagged, not filed as an all-clear.

Frontier AI works the details as a careful lab report reader. It takes the endometrial thickness off the ultrasound and the wording off the pathology report and tells you what each one means for your case, in plain language. Healz has memory that holds every prior result you upload and connects them over time, so a thickness that creeps up across scans, or a bleeding pattern that keeps recurring, surfaces as a trend rather than a one-off.

That is a genuine second opinion on a workup where a miss is costly. When you want a human in the loop, you can bring a board-certified doctor into the same chat for a second opinion.